Clinical Trial Update: Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of secukinumab in adults with new-onset giant cell arteritis who are in clinical remission. The study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Giant Cell Arteritis | Phase 3 | Status: COMPLETED